Výsledky vyhledávání - "Charles Baimbridge"

Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT

Autor: Sara L. Pressel, Anne M. Huml, Joshua I. Barzilay, Mario A. Henriquez, Carol Stanford, Sithiporn Sastrasinh, Jan Basile, Charles Baimbridge, Nelson Kopyt, Barry R. Davis, Mahboob Rahman, Clive Rosendorff, Gail T. Louis

Publikováno v: Clinical Nephrology

Background/Aims: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by baseline estimated glomeru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a4b2f40b791118b59c942806209e3c
http://europepmc.org/articles/PMC4504135

Zobrazit plný text záznamu

Long-Term Follow-Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Autor: Suzanne Oparil, Jeff D. Williamson, John D. Stokes, Jerry O. Ciocon, Charles Baimbridge, Jeffrey L. Probstfield, Thomas J. Hartney, Thomas B. Wiegmann, Lara M. Simpson, L. Julian Haywood, Barry R. Davis, Charles E. Ford, Karen L. Margolis, Richard A. Dart, David E. Mathis, Paula T. Einhorn, J. L. Holtzman, Aloysius B. Cuyjet, David Gordon

Publikováno v: The Journal of Clinical Hypertension. 15:542-554

The Lipid Lowering Trial component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) was a multi-center randomized trial comparing usual care versus treatment with an HMG CoA-reductase inhibitor (pravasta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8708c1fbe1f228807dfd42cf46062d4f
https://doi.org/10.1111/jch.12139

Zobrazit plný text záznamu

Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR

Publikováno v: Clinical Journal of the American Society of Nephrology. 7:989-1002

Summary Background and objectives CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome effic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebaa3fc01e1fd5a1d2b25fb13611271d
https://doi.org/10.2215/cjn.07800811

Zobrazit plný text záznamu

Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?

Autor: Charles Baimbridge, John D. Stokes, L. Julian Haywood, Jeffrey L. Probstfield, Aloysius B. Cuyjet, David E. Mathis, Thomas J. Hartney, Jeff D. Williamson, Thomas B. Wiegmann, Jerry O. Ciocon, Paula T. Einhorn, J. L. Holtzman, Lara M. Simpson, Karen L. Margolis, Suzanne Oparil, David Gordon, Richard A. Dart, Barry R. Davis, Charles E. Ford

Publikováno v: J Clin Hypertens (Greenwich)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7108eacb66d15922dbf982013f97390d
https://pubmed.ncbi.nlm.nih.gov/24299694

Zobrazit plný text záznamu

Clinical Outcomes by Race in Hypertensive Patients with and without the Metabolic Syndrome in ALLHAT

Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensive patients with metabolic/cardiometabolic syndrome (MetS). We compared outcomes by race in hypertensive individuals with and without MetS treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f9f118759252bd310cf6a585a2fa9eac
https://europepmc.org/articles/PMC2805022/

Zobrazit plný text záznamu

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Autor: Jan Basile, Mahboob Rahman, Barry R. Davis, C. Stanford, Anne M. Huml, Charles Baimbridge, Clive Rosendorff, Gail T. Louis, Sara L. Pressel, Mario A. Henriquez, Joshua I. Barzilay, Sithiporn Sastrasinh, Nelson Kopyt

Publikováno v: American journal of kidney diseases : the official journal of the National Kidney Foundation. 52(3)

Background Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear. Study Design Prospective randomized clinical trial, post hoc analyses. Setting & Participants 10,06

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb114a0dbb829e583baea097f6feeb9
https://pubmed.ncbi.nlm.nih.gov/18725010

Zobrazit plný text záznamu

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Autor: Henry R, Black, Barry, Davis, Joshua, Barzilay, Chuke, Nwachuku, Charles, Baimbridge, Horia, Marginean, Jackson T, Wright, Jan, Basile, Nathan D, Wong, Paul, Whelton, Richard A, Dart, Udho, Thadani

Publikováno v: Diabetes care. 31(2)

Optimal initial antihypertensive drug therapy in people with the metabolic syndrome is unknown.We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiova

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5a1f6c3237b02ab9b01b4b8b25b08e7d
https://pubmed.ncbi.nlm.nih.gov/18000186

Zobrazit plný text záznamu

Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic SyndromeAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Publikováno v: Archives of Internal Medicine. 168:207

Background: Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensivepatientswithmetabolic/cardiometabolicsyndrome (MetS). We compared outcomes by race in hypertensiveindividualswithandwithoutMetStre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51ecc71eeb68fe0e65e09797e95f6552
https://doi.org/10.1001/archinternmed.2007.66

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání